Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study
Abstract Background The aim was to investigate psychotropic medication use in parents of survivors of adolescent cancer from the acute post‐diagnostic phase and up to 2 years following the cancer diagnosis. Methods This study had a nationwide register‐based cohort design comparing psychotropic medic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4780 |
| _version_ | 1811319164508307456 |
|---|---|
| author | Anna Wikman Emma Hovén Anette Alvariza Malin Lövgren Ulrika Kreicbergs Charlotte Skoglund Emma Fransson Gustaf Ljungman Rickard Ljung Lisa Ljungman |
| author_facet | Anna Wikman Emma Hovén Anette Alvariza Malin Lövgren Ulrika Kreicbergs Charlotte Skoglund Emma Fransson Gustaf Ljungman Rickard Ljung Lisa Ljungman |
| author_sort | Anna Wikman |
| collection | DOAJ |
| description | Abstract Background The aim was to investigate psychotropic medication use in parents of survivors of adolescent cancer from the acute post‐diagnostic phase and up to 2 years following the cancer diagnosis. Methods This study had a nationwide register‐based cohort design comparing psychotropic medication use in parents of adolescent survivors of cancer (n = 2323) to use in parents of cancer‐free controls (n = 20,868). Cox proportional hazards models, adjusted for cancer diagnostic group, parents' age, country of birth, education level, marital status and previous mental health problems estimated the risk of use from the time of the cancer diagnosis up to 2 years later. Results During the first 6 months after the cancer diagnosis, both mothers and fathers had an increased risk of use of anxiolytics (mothers: HRadj 1.71, 95% CI 1.30–2.25; fathers: HRadj 1.57, 95% CI 1.10–2.45) and hypnotics/sedatives (mothers: HRadj 1.53, 95% CI 1.23–1.90; fathers: HRadj 1.32, 95% CI 1.00–1.75). For fathers with a prescription of psychotropic medication during the first 6 months after the cancer diagnosis, the risk remained increased after 6 months (HRadj 1.66, 95% CI 1.04–2.65). From 6 months after the cancer diagnosis, only the risk of antidepressant use among mothers was increased (HRadj 1.38, 95% CI 1.08–1.76). Risk factors included being divorced/widowed, born in a non‐Nordic country, older age and having had previous mental health problems. Conclusion Our study results show that during the immediate post‐diagnostic phase, mothers and fathers of survivors of adolescent cancer are at increased risk of use of anxiolytics and sedatives, whereas only mothers are at increased risk of antidepressant use from 6 months until 2 years after the diagnosis. Further, previous mental health problems were shown to be the strongest risk factor for psychotropic medication use in both mothers and fathers, pointing to the particular vulnerability of these parents. |
| first_indexed | 2024-04-13T12:38:20Z |
| format | Article |
| id | doaj.art-94cbb12481e14639b7b109980de42214 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T12:38:20Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-94cbb12481e14639b7b109980de422142022-12-22T02:46:36ZengWileyCancer Medicine2045-76342022-11-0111224341435310.1002/cam4.4780Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort studyAnna Wikman0Emma Hovén1Anette Alvariza2Malin Lövgren3Ulrika Kreicbergs4Charlotte Skoglund5Emma Fransson6Gustaf Ljungman7Rickard Ljung8Lisa Ljungman9Department of Women's and Children's Health Uppsala University Uppsala SwedenDepartment of Women's and Children's Health Uppsala University Uppsala SwedenDepartment of Health Care Sciences/Palliative Research Centre Ersta Sköndal Bräcke University College Stockholm SwedenDepartment of Health Care Sciences/Palliative Research Centre Ersta Sköndal Bräcke University College Stockholm SwedenDepartment of Health Care Sciences/Palliative Research Centre Ersta Sköndal Bräcke University College Stockholm SwedenDepartment of Neuroscience Uppsala University Uppsala SwedenDepartment of Women's and Children's Health Uppsala University Uppsala SwedenDepartment of Women's and Children's Health Uppsala University Uppsala SwedenUnit of Epidemiology, Institute of Environmental Medicine Karolinska Institutet Stockholm SwedenDepartment of Women's and Children's Health Uppsala University Uppsala SwedenAbstract Background The aim was to investigate psychotropic medication use in parents of survivors of adolescent cancer from the acute post‐diagnostic phase and up to 2 years following the cancer diagnosis. Methods This study had a nationwide register‐based cohort design comparing psychotropic medication use in parents of adolescent survivors of cancer (n = 2323) to use in parents of cancer‐free controls (n = 20,868). Cox proportional hazards models, adjusted for cancer diagnostic group, parents' age, country of birth, education level, marital status and previous mental health problems estimated the risk of use from the time of the cancer diagnosis up to 2 years later. Results During the first 6 months after the cancer diagnosis, both mothers and fathers had an increased risk of use of anxiolytics (mothers: HRadj 1.71, 95% CI 1.30–2.25; fathers: HRadj 1.57, 95% CI 1.10–2.45) and hypnotics/sedatives (mothers: HRadj 1.53, 95% CI 1.23–1.90; fathers: HRadj 1.32, 95% CI 1.00–1.75). For fathers with a prescription of psychotropic medication during the first 6 months after the cancer diagnosis, the risk remained increased after 6 months (HRadj 1.66, 95% CI 1.04–2.65). From 6 months after the cancer diagnosis, only the risk of antidepressant use among mothers was increased (HRadj 1.38, 95% CI 1.08–1.76). Risk factors included being divorced/widowed, born in a non‐Nordic country, older age and having had previous mental health problems. Conclusion Our study results show that during the immediate post‐diagnostic phase, mothers and fathers of survivors of adolescent cancer are at increased risk of use of anxiolytics and sedatives, whereas only mothers are at increased risk of antidepressant use from 6 months until 2 years after the diagnosis. Further, previous mental health problems were shown to be the strongest risk factor for psychotropic medication use in both mothers and fathers, pointing to the particular vulnerability of these parents.https://doi.org/10.1002/cam4.4780adolescenceantidepressantsanxiolyticschildhood cancerhypnotics/sedativesmental health problems |
| spellingShingle | Anna Wikman Emma Hovén Anette Alvariza Malin Lövgren Ulrika Kreicbergs Charlotte Skoglund Emma Fransson Gustaf Ljungman Rickard Ljung Lisa Ljungman Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study Cancer Medicine adolescence antidepressants anxiolytics childhood cancer hypnotics/sedatives mental health problems |
| title | Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study |
| title_full | Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study |
| title_fullStr | Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study |
| title_full_unstemmed | Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study |
| title_short | Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study |
| title_sort | psychotropic medication use in parents of survivors of adolescent cancer a register based cohort study |
| topic | adolescence antidepressants anxiolytics childhood cancer hypnotics/sedatives mental health problems |
| url | https://doi.org/10.1002/cam4.4780 |
| work_keys_str_mv | AT annawikman psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT emmahoven psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT anettealvariza psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT malinlovgren psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT ulrikakreicbergs psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT charlotteskoglund psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT emmafransson psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT gustafljungman psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT rickardljung psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy AT lisaljungman psychotropicmedicationuseinparentsofsurvivorsofadolescentcanceraregisterbasedcohortstudy |